Periodontal Treatment and Ischemic Stroke
Systemic Effects of Periodontal Therapy on Patients With Ischemic Stroke. A Pilot Randomized Controlled Clinical Trial
1 other identifier
interventional
60
1 country
1
Brief Summary
A bulk of observational evidence suggests an association between periodontitis and recurrent vascular events in ischemic stroke survivors. One plausible biological mechanism relies on the systemic inflammatory response posed by periodontitis together with changes in the normal function of the vascular endothelium which might lead to recurrence in these population. A non-pharmacological anti-inflammatory treatment (non-surgical periodontal therapy) has shown to reduce systemic inflammatory markers and improve endothelial function. Therefore, we propose to carry out a 1-year follow-up pilot randomized controlled clinical trial to investigate whether control of local and systemic inflammation as well as improve function of the vascular endothelium can lead to reduce the risk of recurrence in patients diagnosed from ischemic stroke.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 15, 2021
CompletedFirst Posted
Study publicly available on registry
July 9, 2021
CompletedStudy Start
First participant enrolled
September 29, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 11, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 29, 2023
CompletedSeptember 30, 2021
September 1, 2021
1.1 years
June 15, 2021
September 29, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
IL-6 serum levels
Concentrations of IL-6 in serum will be measured by ELISA technique
from baseline to 6 months after therapy
Secondary Outcomes (8)
Other inflammatory markers
from baseline to 6 months after therapy
Flow-mediated dilatation (brachial artery)
from baseline to 6 months after therapy
Intima-media thickness (carotid artery)
from baseline to 6 months after therapy
Recurrent vascular events
from baseline to 12 months after therapy
Lipid fractions
from baseline to 6 months after therapy
- +3 more secondary outcomes
Study Arms (2)
Non-surgical periodontal therapy
EXPERIMENTALOral hygiene instructions will be given to all individuals. Any hopeless tooth or categorised as irrational to treat at baseline visit will be extracted at the treatment visit(s). Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments .
Conventional periodontal therapy
ACTIVE COMPARATOROral hygiene instructions will be given to all individuals. Any hopeless tooth or categorised as irrational to treat at baseline visit will be extracted at the treatment visit(s). Supragingival cleaning and polishing of all dentition will be delivered to individuals in this group.
Interventions
Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments.
Eligibility Criteria
You may qualify if:
- Aged \>18 years old.
- Non-severely disabling initial ischemic stroke (mRS≤3) in the last 90 days.
- With diagnosis of severe periodontitis (generalized stage III-IV).
- Presence of at least 10 teeth in the mouth.
You may not qualify if:
- Patients receiving periodontal treatment in the last 12 months.
- Stroke due to intracranial hemorrhage, dissection, veno-occlusive disease, drugs, trauma or vasculitis.
- Previous neurological impairment that would make detection of a subsequent event difficult.
- Comorbidities that may limit survival \<12 months.
- Brain CT/MRI that shows a lesion other than stroke as a cause of syndrome.
- History of medical conditions requiring antibiotic prophylaxis prior to dental exam.
- Pregnants or breastfeeding.
- Known allergy or hypersensitivity to local anesthesia thst cannot be medically managed.
- Patients with bleeding disorders or
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Santiago de Compostela
Santiago de Compostela, A Coruña, 15782, Spain
Related Publications (1)
Ye Z, Cao Y, Miao C, Liu W, Dong L, Lv Z, Iheozor-Ejiofor Z, Li C. Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis. Cochrane Database Syst Rev. 2022 Oct 4;10(10):CD009197. doi: 10.1002/14651858.CD009197.pub5.
PMID: 36194420DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yago Leira, PhD
Health Research Institute of Santiago
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 15, 2021
First Posted
July 9, 2021
Study Start
September 29, 2021
Primary Completion
November 11, 2022
Study Completion
December 29, 2023
Last Updated
September 30, 2021
Record last verified: 2021-09
Data Sharing
- IPD Sharing
- Will not share